Verified peer comparison

DHR vs ABBV

Danaher Corporation compared with AbbVie Inc.. This page compares both source-verified company profiles and does not introduce an unverified price target.

DHR

Danaher Corporation

$189.43

Open: --
High: --
Low: --
Market Cap: --

Open stock research

ABBV

AbbVie Inc.

$189.43

Open: --
High: --
Low: --
Market Cap: --

Open stock research

Company-specific comparison

Business exposure

DHR: Life Sciences Tools and Services

ABBV: Biotechnology

Upside lens

DHR: Normalization in large-pharma and biotech ordering can restore growth in consumables and equipment. A large installed base in life sciences and diagnostics supports repeat reagent, service and consumable demand. Disciplined integration of Masimo can broaden specialty diagnostics and create operating-improvement opportunities.

ABBV: Continued Skyrizi and Rinvoq adoption is expanding AbbVie's immunology portfolio and replacing revenue lost after Humira's U.S. exclusivity expiry. Growth across Vraylar, Botox Therapeutic, the migraine portfolio, and Vyalev broadens AbbVie's growth base beyond immunology. Regulatory submissions, approvals, and key clinical data readouts expected over the next year could add indications and reinforce the post-Humira portfolio transition.

Risk lens

DHR: Weak biotechnology funding or customer destocking could delay a sustained order recovery. Large acquisitions can bring debt, execution, regulatory and synergy-realization risk. Procurement policy, local competition and macro weakness can pressure diagnostics and life-science demand.

ABBV: Humira revenue continues to contract after biosimilar entry, leaving execution on replacement growth products essential to the portfolio transition. Imbruvica declines are weighing on oncology, requiring growth from Venclexta, Elahere, and pipeline assets to offset the mature brand. U.S. drug-pricing policy, including the selection of Botox for Medicare negotiated prices beginning in 2028, could pressure future revenue and margins.